From Evidence to Impact:
Notes on Dr. Rodica Busui’s Grand Rounds on the Landmark Diabetes Trials
By Thomas Lee Abshier, ND | 15 November 2026
Watch the original lecture: From Evidence to Impact: Lessons Learned from Landmark Diabetes Trials Shaping Today’s and Tomorrow’s Care — Providence Medical Grand Rounds, September 15, 2026. Providence Grand Rounds video playlist (direct video link to be added)
Why I am writing about this lecture
I attend Providence Medical Grand Rounds for my continuing medical education, and I am grateful that Providence makes these sessions available live, online, and by recording. Grand Rounds is a joint effort of Providence St. Vincent Medical Center and Providence Portland Medical Center, and this session, held at St. Vincent, was the annual Huldrick Kammer Endocrine Lectureship.
Dr. Michael McClung introduced the lectureship. Dr. Kammer was the first board-certified endocrinologist in Oregon, arriving in the 1940s. He practiced at Good Samaritan Hospital while collaborating with the medical school, and when Dr. David Gilbert came to lead medicine at what is now Providence Portland Medical Center, he recruited Dr. Kammer to the medical education faculty, where he served until his death in 2003. He was remembered as intellectually curious, compassionate with patients, and a model of how to combine clinical expertise, clinical research, and teaching. Dr. Gilbert added a few affectionate stories during the question period: Dr. Kammer making him explain the radioimmunoassay over and over until Dr. Gilbert conceded that Dr. Kammer knew more about it, and photographs of Dr. Kammer chasing the family dog around the yard to collect a urine specimen when the dog developed diabetes.
The lecturer was Dr. Rodica Busui, MD, PhD, Professor of Medicine, Jordan Schnitzer Chair in Diabetes, Chief of the Division of Endocrinology, Diabetes and Clinical Nutrition at Oregon Health & Science University, and Director of the Harold Schnitzer Diabetes Health Center. She was the 2023 President for Medicine and Science of the American Diabetes Association. Before coming to Oregon she was at the University of Michigan, where she built patient cohorts that taught the field a great deal about diabetes and its complications, and she has helped lead many of the landmark trials she discussed, including DCCT/EDIC and ACCORD.
What follows is my organized summary of the lecture, with my own commentary in a clearly marked section. I have paraphrased throughout, and any errors are mine, not Dr. Busui’s. I encourage every clinician and student to watch the lecture itself; Dr. Busui’s warmth and her personal recollections of the investigators behind these trials come through best in her own voice.
In brief. Forty years of diabetes trials have taught three lessons. First, controlling blood sugar early and keeping it controlled pays off for decades, an effect called “metabolic memory.” Second, lower is not always better: how a target is reached, and in whom, matters as much as the number. Third, diabetes is more than glucose. Newer drug classes protect the heart and kidneys in ways that go beyond lowering blood sugar, and new technology lets people with type 1 diabetes reach targets with less hypoglycemia. Care must be personalized, must treat the organs and not just the number, and must be shared across every specialty, because, as Dr. Busui put it, healthcare may be siloed but people with diabetes are not.
Dr. Busui’s disclosure and plan
Dr. Busui disclosed research funding from NIH and foundations, and collaboration with industry partners in designing several of the trials she would discuss. Her plan was to trace the journey from a simple question (does lowering glucose prevent complications?) to today’s integration of data, medications, and technology, and to ask what that journey means for the individual patient in front of us.
She opened with two patients. The first was Maria, a young woman with type 1 diabetes for eight years, an A1C of 9.4, wide swings between high and low blood sugars, and no clinically evident complications yet. The second was a man with type 2 diabetes whose A1C of 5 might seem reassuring, but who also had obesity, kidney dysfunction, and a prior heart attack. What should we do first for each? The rest of the lecture supplied the answer.
Why diabetes matters so much
Dr. Busui described diabetes as the most prevalent and most challenging chronic disease we face. About 40 million people in the United States have diagnosed diabetes, roughly 400,000 of them in Oregon, about one in ten people, and the costs are unsustainable.
She recalled her own professor in medical school in Romania, a pioneer in diabetes care working without today’s technology, who taught that if you know diabetes, you know internal medicine. The disease touches nearly every organ: the classic eye, kidney, and nerve complications; cardiovascular disease, with heart failure now the most prevalent cardiovascular complication; cognitive decline and Alzheimer’s disease, for which she identified diabetes as a major driver; foot complications, the leading cause of non-traumatic amputations, with CDC data she described as showing an appalling recent increase in amputation rates; neurological and sexual dysfunction; and the daily psychosocial burden of living with the disease. Diabetes shortens life. She also highlighted a striking observation: the relative protection women have against cardiovascular and kidney disease in the absence of diabetes is erased, and even reversed, in women with type 1 or type 2 diabetes, as documented particularly for heart failure and diabetic kidney disease.
The foundation: does lowering glucose prevent complications?
DCCT: the trial that created the standards of care
Because diabetes is defined by high blood sugar, the first question was whether normalizing glucose would prevent or delay long-term complications. The Diabetes Control and Complications Trial (DCCT), designed in the 1980s, enrolled very young people with type 1 diabetes (mean age about 20, including adolescents). Intensive therapy, using the means available then, did not reach normal glucose, but kept A1C around 7% for about six and a half years, compared with about 9% under the usual care of the time.
The trial was stopped early because the benefits were so large: dramatic reductions in retinopathy, kidney disease, and neuropathy. Before the DCCT there were no standards of care in diabetes; its results led the American Diabetes Association to create the first ones.
Dr. Busui shared a story she heard from the late Drs. Saul Genuth and Oscar Crofford, two of the fathers of the DCCT. When they proposed it, the safety monitoring board and NIDDK initially worried the trial would kill patients by driving glucose so low. The reality proved the opposite: the DCCT showed that the biological course of the disease could be changed. The price was real, however: substantially more hypoglycemia and more weight gain.
EDIC and “metabolic memory”
NIDDK, in its wisdom, decided to keep following DCCT participants in the Epidemiology of Diabetes Interventions and Complications (EDIC) study. More than 40 years after enrollment, every surviving participant still comes in every year. When the trial ended in 1993, everyone was advised to pursue near-normal glucose, but that proved very hard in real life, and within three to four years the A1C difference between the former intensive and conventional groups disappeared, settling around 7.8 to 7.9%.
Yet the former intensive group kept its advantage: lower risk of retinopathy for at least 18 years of follow-up, of kidney disease, of neuropathy (seen up to 14 years), and eventually of cardiovascular disease, which became visible about ten years after the DCCT ended because the cohort was so young at entry. Later analyses showed mortality in the former intensive group similar to that of the general population, much less cognitive decline, and benefits for urologic and some psychological complications. This persistence of benefit is called metabolic memory: early, sustained glucose control changes the future.
Dr. Busui said she is humbled when patients who have lived with type 1 diabetes for 40 or 50 years tell her that, at diagnosis, their parents were told they might not live to 30, would never have children, and would die on dialysis or lose their legs. Well-designed clinical questions and trials changed that course.
UKPDS: the type 2 counterpart
Ninety percent of people with diabetes have type 2. The United Kingdom Prospective Diabetes Study (UKPDS), using the drugs of its era (sulfonylureas, insulin, and metformin), showed that intensive glucose control in early type 2 diabetes reduced eye and kidney complications by about 25%, with an A1C difference of roughly 7% versus 8%. There was no initial cardiovascular benefit, but with 20 years of follow-up the investigators saw significant reductions in heart attacks and mortality, along with lasting microvascular benefit. The legacy effect appears in type 2 diabetes too, but it takes time.
Is lower always better?
ACCORD
The ACCORD trial, the largest of its time, funded by the National Heart, Lung, and Blood Institute and enrolling more than 10,000 patients, asked whether pushing A1C below 6% would finally show the cardiovascular benefit UKPDS had not shown at first. Oregon was a site, led by Dr. Busui’s friend, the late Dr. Matt Riddle, whom she called a visionary. To reach the target, investigators could combine any insulins, sulfonylureas, and thiazolidinediones, the tools of the time.
The A1C separation was achieved, but the intensive intervention was stopped after about three and a half years. The primary composite of major cardiovascular events trended about 10% lower, but all-cause mortality was significantly higher. The trial’s factorial arms also tested adding a fibrate to a statin and targeting systolic blood pressure below 120 versus below 140; neither changed the main outcomes. The lesson, she said, is caution about when and how to pursue intensive targets, especially in people like those in ACCORD, who had established cardiovascular disease or multiple risk factors, quite unlike the newly diagnosed patients of UKPDS. Lowering glucose by any means in such patients may be harmful.
ADVANCE and VADT
Perspective matters. ADVANCE, with a similar design but a gentler approach (an A1C target below 6.5%, in Europe, Australia, and Asia), enrolled even more people. It showed no mortality or cardiovascular harm and did reduce microvascular complications; ACCORD, too, reduced kidney disease and retinopathy, though higher mortality had to color everything. The VA Diabetes Trial (VADT), in an older, sicker population with a baseline A1C around 9%, showed neither benefit nor harm.
Matt Riddle’s question
Dr. Busui credited Dr. Riddle for refusing to let the ACCORD mortality finding rest. Working with colleagues at the trial’s data coordinating center at Wake Forest, he found that the people who died in the intensive arm were largely those who never reached the lower A1C. Their A1C stayed high while they received large amounts of insulin and sulfonylureas and gained weight. Hypoglycemia contributed, but deaths related to hypoglycemia did not differ much between the arms. The lesson is not simply that low A1C is dangerous; it is that the means used to chase a target can matter enormously.
The summary lesson: individualize
Glycemic targets must be individualized. Early, intensive control matters, especially in type 1 diabetes. Hypoglycemia is a real cost; severe hypoglycemia was far more frequent with intensive treatment in DCCT, ACCORD, and ADVANCE. The legacy effect takes time, appearing 6 to 15 years later in DCCT and more than 10 years later in UKPDS. That is why today’s standards of care set A1C targets according to the patient.
GRADE: which second drug?
The NIDDK-funded GRADE trial, also conducted in Oregon under Dr. Riddle, was designed when metformin plus lifestyle was the universal first step and before SGLT2 inhibitors were approved. It asked which second drug, added to metformin in people with relatively recent type 2 diabetes, best maintained an A1C below 7%: a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 receptor agonist (liraglutide), or basal insulin (glargine). Liraglutide and glargine were the most durable; glimepiride and sitagliptin failed soonest. The trial was not powered for heart or kidney outcomes, though the liraglutide arm showed cardiovascular benefit. On a composite that also counted weight gain over 5% and severe or recurrent hypoglycemia, glimepiride and insulin carried the highest risk and liraglutide the lowest. How we reach the target, with the least weight gain and hypoglycemia, matters as much as reaching it.
Beyond A1C: diabetes is more than glucose
Even in the DCCT cohort, some people with good A1C developed complications and some without good control did not. Something more than glucose is at work.
The FDA decision of 2008
Dr. Busui called it perhaps one of the best decisions the FDA ever made. In 2007 to 2008, after Dr. Steven Nissen’s meta-analysis in the New England Journal of Medicine raised concern that rosiglitazone increased cardiovascular risk, the diabetes field was in turmoil. The FDA then required that new diabetes drugs show long-term cardiovascular safety. It asked only for safety, but the resulting cardiovascular outcome trials uncovered benefit and gave us two transformative drug classes.
SGLT inhibitors
SGLT2 (and now SGLT1/2) inhibitors, she said, are rewiring vascular biology. In the kidney they lower the pressure inside the filtering units; they improve hemodynamics and so benefit heart failure; and they shift the heart’s fuel use toward fatty acids and ketones, which are efficient substrates, delaying the progressive cardiac dysfunction of diabetes. They do raise the risk of ketone generation. EMPA-REG OUTCOME with empagliflozin was the first trial to show not just safety but superiority, with a large reduction in death. CANVAS and then CREDENCE with canagliflozin followed, with major reductions in kidney outcomes, including end-stage kidney disease. DECLARE, DAPA-HF, DAPA-CKD, and EMPA-KIDNEY extended benefit to people with heart failure, chronic kidney disease, and even prediabetes.
GLP-1 receptor agonists
GLP-1 receptor agonists have also revolutionized the field, acting on many targets: improved endothelial function (shown for the first time in analyses and a kidney biopsy substudy of the FLOW trial), strong anti-inflammatory effects, plaque stability, insulin sensitivity, and hemodynamics. Beginning with LEADER (liraglutide), followed by trials of semaglutide, dulaglutide, and, most recently, tirzepatide and oral semaglutide, these drugs have consistently reduced major cardiovascular events by roughly 13 to 15%, with added kidney benefit. FLOW was stopped early because its kidney endpoint (doubling of creatinine and end-stage kidney disease) was reached sooner than expected.
Dr. Busui dwelt on SOUL, the oral semaglutide trial, because many had doubted that an oral GLP-1 drug could be absorbed well enough, or taken faithfully enough, to work. It did. In people with diabetes and heart failure at baseline, oral semaglutide reduced heart failure events by about 22%, even though 28% were already on an SGLT2 inhibitor. Together with SELECT (in obesity without diabetes), SOUL eased cardiologists’ earlier concern that GLP-1 drugs might be unsafe in heart failure. Both the injectable (STRIDE) and oral (SOUL) forms also improved outcomes in peripheral arterial disease, a major driver of amputation, including functional outcomes in STRIDE and acute and chronic limb ischemia in SOUL. Benefits for fatty liver disease, sleep apnea, arthritis, and even addiction were, she said, a talk for another day.
Finerenone, and fairness to type 1 diabetes
The nonsteroidal mineralocorticoid receptor antagonist finerenone targets fibrosis and inflammation in the kidney and heart. In FIDELIO-DKD and FIGARO-DKD it reduced both cardiovascular and kidney risk.
Dr. Busui then made a point she clearly feels deeply: people with type 1 diabetes were systematically excluded from nearly all of these trials, which she called extremely unfair, since cardiovascular and kidney disease remain the leading causes of death in type 1 diabetes as well. She commended Bayer for FINE-ONE, a trial limited to type 1 diabetes, which showed that finerenone reduced albuminuria. She also thanked Breakthrough T1D for funding SUGARNSALT, a large trial underway at OHSU testing sotagliflozin in type 1 diabetes with a goal of FDA approval. Because diabetic ketoacidosis has always been the concern, the trial uses continuous glucose monitors, pumps, ketone monitoring, and a carefully designed mitigation algorithm. After more than 100 participants enrolled, most for at least a year, there had been no DKA events.
Technology: reaching targets without hypoglycemia
The DCCT taught that lower glucose matters, but at the cost of hypoglycemia and weight gain. Technology has been the answer for type 1 diabetes. Automated insulin delivery systems such as Tandem’s Control-IQ and Medtronic’s MiniMed 780G, along with newer adaptive algorithms that recalculate insulin delivery every five minutes from the changing glucose trend, have increased time in range (70 to 180 mg/dL) while reducing hypoglycemia. OHSU and Stanford are beginning a trial of a Tidepool fully automated system that requires no carbohydrate counting at all. The pace of progress, she said, is mind-boggling and excellent for patients.
For type 2 diabetes, she has no doubt that continuous glucose monitoring is a phenomenal tool. She described a trial her group designed as a partnership between endocrinologists and primary care physicians, communicating through the electronic health record. Patients were randomized to blinded or open CGM, the reports were uploaded to the record, the primary care physician made the decisions, and the endocrinologist was available for initial advice on reading the reports. The result was a meaningful improvement in A1C, more time in range, and much less hypoglycemia, which is further proof that the way forward is partnership among everyone who cares for patients with diabetes.
Dr. Busui’s perspective and four takeaways
Looking back on decades of evidence, Dr. Busui recalled a moment from the planning of ACCORD. Investigators worried aloud that no one would agree to be randomized, because every patient would want the intensive arm, and everyone knew lower was better. Dr. Saul Genuth replied that they did not know; they assumed they knew, and until a trial proved it, they did not. That, she said, is how to explain trials to participants.
The practical result is that the ADA Standards of Care, updated every year, and the ADA/EASD consensus report no longer say that everyone starts with metformin. For a patient with high cardiovascular risk, established cardiovascular disease, or heart failure, the first-line choice is a GLP-1 receptor agonist, an SGLT2 inhibitor, or both, tailored by additional factors. Medications can now be fitted together like a puzzle to each patient’s clinical and biological profile, which is true precision care.
Her four takeaways:
- Early and durable control matters.
- One target does not fit all. Personalize.
- Treat the organ, not just the number. Address every risk factor for metabolic and vascular health, using medications, technology, or both.
- We cannot wait, and we must work together. She recalled hearing cardiology colleagues in trial meetings suggest that diabetologists were no longer needed. Diabetes, she answered, does not belong to the diabetologist, the nephrologist, or the cardiologist. It belongs to all of us, because although healthcare may be siloed, people with diabetes are not.
Dr. McClung thanked her for a lecture he found thoughtful and inspiring, particularly for the confidence it gives primary care clinicians to engage fully in diabetes management.
From the question period
Hypoglycemia, memory, and protecting the brain. A primary care physician asked about memory decline and whether hypoglycemia contributes to dementia. Dr. Busui said EDIC studied exactly this after the DCCT’s higher hypoglycemia rates raised concern. The answer was the opposite of what was feared: severe hypoglycemia, an acute event, was not associated with cognitive decline in type 1 diabetes, while persistently high glucose was. In a comprehensive recent study combining cognitive testing and brain MRI across the whole cohort, now averaging about 64 to 65 years old, a sustained 1% higher A1C had an effect on the brain greater than five to seven years of aging. In type 2 diabetes, the link to dementia and Alzheimer’s disease is clear from biology to clinical data. GLP-1 receptor agonists were the first drug class to show a significant reduction in stroke, which can contribute to dementia, though trials designed specifically to slow cognitive decline have not yet shown benefit.
Where can primary care find usable guidance? Dr. Busui pointed to the ADA’s Primary Care Alliance, a national initiative partnering endocrinologists and primary care physicians, and to abridged versions of the Standards of Care, since the full document runs over 300 pages. At OHSU, a diabetes quality improvement task force uses electronic health record data to identify patient profiles and prompt clinicians, in primary care and endocrinology alike, when something is missing: a urine albumin test, a statin, an ACE inhibitor or ARB, not only a GLP-1 drug. When the work began, some clinicians felt certain all their patients were already on an ACE inhibitor or ARB; the data showed that only about 45% of those who should be were. The pandemic, missed visits, and fragmented continuity all contributed. The tools now exist to close these gaps, and it is a team effort.
The microbiome. Dr. Gilbert, after his Kammer stories, made a plea for the microbiome and for infectious disease on the list of specialties involved in diabetes. With each advance improving outcomes by 10 to 20%, he said, it feels as though we are sniffing around the edges of a big breakthrough, and that one day the dam will break and we will understand the root cause of the diabetic disorders. Dr. Busui agreed that infection is central to foot complications, osteomyelitis, and amputation, and that the microbiome is fascinating, though hard to study because so many factors affect it and cohort results have conflicted.
My reflections
This section is my own commentary, not part of the lecture.
This lecture was a gift to anyone who wants to understand not only what we do in diabetes care but why. Dr. Busui has been inside many of these trials, and she told their history the way it was lived: the safety board that feared the DCCT would kill patients, the colleague who would not stop asking why ACCORD’s intensive arm died more, the trialist who reminded everyone that assuming is not knowing. Her generosity in crediting colleagues, especially the late Dr. Matt Riddle, was evident throughout.
Three lessons stay with me.
First, the body keeps a record. Metabolic memory is one of the most hopeful and sobering findings in medicine. What we do early echoes for decades, for good or ill. That truth is an argument for acting early and steadily, and for helping patients understand that the years before complications appear are the years that count most.
Second, the means matter as much as the target. ACCORD and Dr. Riddle’s analysis teach that a number can be pursued in ways that harm. A good clinician asks not only “Is the A1C at goal?” but “How did we get here, at what cost in hypoglycemia and weight, and what is happening to the heart, kidneys, brain, and feet?” Dr. Busui’s phrase, treat the organ and not just the number, is a good motto for all of medicine.
Third, the patient belongs to everyone who cares for him. Her closing line, that healthcare may be siloed but people with diabetes are not, applies to every clinician who sees a person with diabetes, including those of us who work in primary care and natural medicine. In my own practice I place diet and lifestyle at the foundation of chronic disease care, and I have long believed that most type 2 diabetes is driven by how we eat and live. I read these trials as showing, with unusual clarity, what is at stake when that foundation is neglected and how much can be preserved when glucose is brought under control early. Dr. Gilbert’s remark that we may be circling a deeper understanding of the root causes of the diabetic disorders resonated with me as well.
I am grateful to Dr. Busui for a lecture that was learned, humane, and full of hope; to Dr. McClung for hosting the Kammer Lectureship; and to Providence for keeping alive a teaching tradition that Dr. Kammer helped build. Please watch the original.
A reader’s guide: questions to ask about any patient with diabetes
Drawn from the lecture:
- Is this early disease, where intensive, sustained control can create lasting metabolic memory?
- What A1C target fits this person’s age, history, cardiovascular disease, and risk of hypoglycemia?
- How is the target being reached, and at what cost in hypoglycemia and weight gain?
- Does this patient have heart failure, cardiovascular disease, or kidney disease that calls for an SGLT2 inhibitor, a GLP-1 receptor agonist, or both, regardless of A1C?
- Are the basics in place: urine albumin testing, statin, ACE inhibitor or ARB?
- Would continuous glucose monitoring, or for type 1 diabetes automated insulin delivery, make the target safer to reach?
- Are the feet, eyes, kidneys, and memory being watched?
- Who else should be on this patient’s team?
Editorial notes
These notes clarify points from the lecture for readers who want to follow up. They are mine, not the speaker’s.
- DCCT figures. Intensive therapy reduced the risk of developing retinopathy by 76% in the primary-prevention cohort, slowed its progression by 54% in the secondary-intervention cohort, reduced albuminuria by 54%, and reduced clinical neuropathy by 60%, with a two- to three-fold increase in severe hypoglycemia (DCCT Research Group, N Engl J Med 1993;329:977–86).
- EMPA-REG OUTCOME date and results. The recording gives the year as 2005; the results were presented and published in September 2015. Empagliflozin reduced the composite of major cardiovascular events by 14%, cardiovascular death by 38%, all-cause death by 32%, and heart failure hospitalization by 35% (Zinman et al., N Engl J Med 2015).
- Dr. Riddle’s ACCORD analysis. The analysis appeared in Diabetes Care in 2010. It found that higher average on-treatment A1C was the stronger predictor of death and that excess risk with the intensive strategy appeared only when average A1C stayed above 7%. In a companion commentary Dr. Riddle noted that the excess mortality was a 22% relative increase, from about 1.1% to 1.4% of participants per year, and that severe hypoglycemia was infrequently associated with death in either arm.
- The ACE/ARB figure. The recording is unclear at this point; I have rendered it as only about 45% of eligible patients receiving these drugs, which fits the context of her remarks.
- Spelling and names. The correct forms are Huldrick Kammer, Rodica Busui (also published as Rodica Pop-Busui), Saul Genuth, Oscar Crofford, and Matthew (Matt) Riddle.
- SOUL. The oral semaglutide trial was presented at the EASD 2025 meeting, with a 14% reduction in major adverse cardiovascular events, comparable to injectable GLP-1 therapies.
Sources
- Providence Medical Grand Rounds, From Evidence to Impact: Lessons Learned from Landmark Diabetes Trials Shaping Today’s and Tomorrow’s Care, Rodica Busui, MD, PhD, September 15, 2026. Providence Grand Rounds playlist.
- OHSU, Rodica Busui, MD, PhD — faculty profile.
- Providence Portland Medical Center, Endowed Lectures (Huldrick Kammer Lecture).
- NIDDK, DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study; EDIC Background Summary.
- Riddle MC, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33(5):983–90.
- Riddle MC. Counterpoint: Intensive Glucose Control and Mortality in ACCORD — Still Looking for Clues. Diabetes Care. 2010;33(12):2722–24.
- American College of Cardiology, SGLT2 Inhibition With Empagliflozin and Cardiovascular Outcomes.
- OHSU Harold Schnitzer Diabetes Health Center, Research studies (including SUGARNSALT).
- Diabetes Insights, Results from the SOUL Trial: The Diabetologists’ Perspective (interview with Dr. Busui).